✦ LIBER ✦

A comparison of ARMS and direct sequencing forEGFRmutation analysis and Tyrosine Kinase Inhibitors treatment prediction in body fluid samples of Non-Small-Cell Lung Cancer patients

✍ Scribed by Yi Liu; Bing Liu; Xiao-Yan Li; Jian-Jie Li; Hai-Feng Qin; Chuan-Hao Tang; Wan-Feng Guo; Hai-Xu Hu; Sha Li; Cui-Jing Chen; Bing Liu; Hong-Jun Gao; Xiao-Qing Liu

Book ID: 115025402
Publisher: BioMed Central
Year: 2011
Tongue: English
Weight: 396 KB
Volume: 30
Category: Article
ISSN: 1756-9966
DOI: 10.1186/1756-9966-30-111

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Relationship between skin rash and outco

Relationship between skin rash and outcome in non-small-cell lung cancer patients treated with anti-EGFR tyrosine kinase inhibitors: A literature-based meta-analysis of 24 trials

✍ Petrelli, Fausto; Borgonovo, Karen; Cabiddu, Mary; Lonati, Veronica; Barni, Sand 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 521 KB

Survivin mRNA expression in blood as a p

Survivin mRNA expression in blood as a predictor of the response to EGFR-tyrosine kinase inhibitors and prognosis in patients with non-small cell lung cancer

✍ Shi, Wei-Lin; Li, Jian; Bao, Quan-Lei; Wu, Jian-Nong; Ge, Li-Ping; Zhu, Li-Rong; 📂 Article 📅 2014 🏛 Springer US 🌐 English ⚖ 514 KB

Overview of molecular testing in non-sma

Overview of molecular testing in non-small-cell lung cancer: mutational analysis, gene copy number, protein expression and other biomarkers of EGFR for the prediction of response to tyrosine kinase inhibitors

✍ John, T; Liu, G; Tsao, M-S 📂 Article 📅 2009 🏛 Nature Publishing Group 🌐 English ⚖ 293 KB

Epidermal growth factor receptor (EGFR)

Epidermal growth factor receptor (EGFR) mutations in a series of non-small-cell lung cancer (NSCLC) patients and response rate to EGFR-specific tyrosine kinase inhibitors (TKIs)

✍ Elena María Martínez-Navarro; Joseba Rebollo; Ramón González-Manzano; Manuel Sur 📂 Article 📅 2011 🏛 Springer Milan 🌐 Spanish ⚖ 230 KB

PD-159 Mutation in the tyrosine kinase d

PD-159 Mutation in the tyrosine kinase domain of epidermal growthfactor receptor (EGFR) is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer (NSCLC)

✍ Tsai, C.; Chiu, C.; Chou, T.; Li, L.; Chang, K.; Chen, Y.; Tsai, S.; Perng, R. 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 139 KB

PCN73 Economic Analysis of the Use of Cr

PCN73 Economic Analysis of the Use of Crizotinib, a Tyrosine Kinase ALK Inhibitor, in the Treatment of ALK Positive Non-Small Cell Lung Cancer in the Mexican Setting

✍ J.G. Gay-Molina; R. Sánchez-Kobashi; E. Muciño-Ortega; C.I. Gutiérrez-Colín; R.M 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 60 KB